Gold
Syndax Pharmaceuticals
- Kelly Wilson
- February 7, 2025
- No Comments
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company’s pipeline include a menin inhibitor for R/R acute leukemia and a monoclonal antibody that blocks the CSF-1 receptor for chronic graft-versus-host disease. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full…
Iovance Biotherapeutics
- Kelly Wilson
- June 14, 2024
- No Comments
About Iovance Biotherapeutics Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance…
Eagle Pharmaceuticals
- Kelly Wilson
- February 14, 2024
- No Comments
Eagle is a fully diversified pharmaceutical company working to advance safe and effective treatments for critical care and oncology patients, their care teams, and the overall health system. https://www.eagleus.com/about/
Immunocore, LLC
- Amanda Bridges
- February 27, 2023
- No Comments
Immunocore, LLC is a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
Aveo Oncology, an LG Chem company
- Amanda Bridges
- May 2, 2022
- No Comments
About Us AVEO Oncology (“AVEO”) is an oncology-focused biopharmaceutical company committed to providing innovative solutions to improve cancer patients’ lives. On January 20, 2023, AVEO was acquired by LG Chem, Ltd. (“LG Chem”), establishing a U.S. commercial presence for LG Chem and expanding LG Chem’s global oncology portfolio. AVEO continues to commercialize FOTIVDA® (tivozanib) in…
Caris Life Sciences
- Amanda Bridges
- May 12, 2021
- No Comments
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. MI Exome™…
Apellis Pharmaceuticals, Inc.
- Amanda Bridges
- January 25, 2021
- No Comments
We Are Apellis We understand that living with a serious disease–like PNH–can pose many challenges and needs that can remain unaddressed. As leaders in developing targeted C3 therapies, we aim to address these needs by leveraging courageous science, creativity, and compassion to develop transformative therapies for a broad range of debilitating diseases that are driven…
Blue Earth Diagnostics, Inc.
- Katrina Williams
- January 8, 2021
- No Comments
Blue Earth Diagnostics, a subsidiary of Bracco Imaging S.p.A., is a recognized leader in the development and commercialization of novel PET radiopharmaceuticals to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by proven experts in nuclear medicine, who have expanded…
Natera
- Katrina Williams
- September 4, 2019
- No Comments
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types…
Coherus Biosciences
- Katrina Williams
- February 6, 2019
- No Comments
Coherus is focused on developing and commercializing a diversified portfolio of immuno-oncology therapies. The advancement of multiple clinical stage candidates underscores our commitment to immuno-oncology treatments while the biosimilar business enables us to provide better access to therapy for patients with life-altering illnesses. About Coherus Solutions™ Coherus is committed to supporting patients with reimbursement and…
Rigel Pharmaceuticals
- Amanda Bridges
- September 24, 2018
- No Comments
Rigel Pharmaceuticals, Inc. is a South San Francisco-based biopharmaceutical company focused on discovering, developing, and providing novel therapies that enhance the lives of people with immune and hematological disorders, cancers, and rare diseases. Rigel’s clinical development programs span multiple disease targets including chronic immune thrombocytopenia, autoimmune hemolytic anemia and others. Rigel’s first FDA approved product…
Agios Pharmaceuticals
- Amanda Bridges
- April 12, 2018
- No Comments
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has an approved oncology precision medicine and multiple first-in-class investigational therapies in clinical and/or preclinical…
Novocure
- Amanda Bridges
- August 2, 2017
- No Comments
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune® – the TTFields delivery system for glioblastoma (GBM) – was launched in the U.S. for the treatment of recurrent…
Adaptive Biotechnologies®
- Amanda Bridges
- March 16, 2017
- No Comments
Adaptive Biotechnologies Company Description Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the…
Exelixis, Inc.
- Amanda Bridges
- June 7, 2016
- No Comments
Founded in 1994, Exelixis is a biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines. Visit our website to learn more. https://www.exelixis.com.
Biotheranostics, a Hologic Company
- Amanda Bridges
- May 12, 2016
- No Comments
Biotheranostics, Inc. represents the oncology portfolio within the Diagnostic Solutions division of Hologic, Inc. The CLIA certified, CAP accredited laboratory provides two proprietary, highly differentiated molecular diagnostic tests for breast and metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID, respectively. Breast Cancer Index (BCI) Breast Cancer Index (BCI) is the only genomic test recognized…
Cencora Specialty GPOs & Oncology Supply
- April 26, 2015
- No Comments
Cencora, formerly AmerisourceBergen, empowers oncology physician practices and ensures their patients have access to the most innovative and cost-effective specialty care close to home. Through our ION Oncology Specialty GPO Network and Oncology Supply specialty distribution, along with our portfolio of integrated Specialty Solutions, we are a unified team of specialty practice partners, committed to…
Bayer
- Amanda Bridges
- February 20, 2015
- No Comments
Products, People and Programs Making a Difference For over 150 years Bayer has been an innovation company rooted in science. Our presence in the U.S. harkens back to the mid-19th century as a chemical company making dyes in Albany, NY. However, by the late-19th century we moved into the healthcare field with the introduction of…
